Cetuximab

Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

By

Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the ASCO 2016 Annual Meeting were told.

Biomarker Indicates Which Patients With Colorectal Cancer Will Respond to Cetuximab

By

A blood-based test pinpoints which patients with metastatic colorectal cancer will benefit from treatment with cetuximab.

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

By

[Clin Med Insights Oncol] Hypersensitivity reactions are a classic and serious side effect of cetuximab.

Combined cetuximab and chemotherapy may speed colorectal cancer progression

By

Cetuximab, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings and may even result in more rapid cancer progression.

Cetuximab enables liver metastasis surgery in colorectal cancer

Combining cetuximab (Erbitux) with standard therapy improved the resectability of previously inoperable liver metastases of colorectal cancer.

New patterns of dermatologic toxicity with radiation and EGFR blockade

New patterns of dermatologic toxicity with radiation and EGFR blockade

By

Emerging combination radiotherapy regimens are improving overall survival; however, associated dermatologic toxicities pose unique challenges.

FDA Update - July/August 2012

News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik

High EGFR plus cetuximab extends survival in lung cancer

People with advanced non-small cell lung cancer tumors expressing high levels of epidermal growth factor receptor are more likely to benefit when cetuximab (Erbitux) is used with chemotherapy.

Combination therapy in metastatic CRC

Adding cetuximab to the treatment regimen of patients with metastatic colorectal cancer (CRC) results in worse outcomes, a controlled trial has shown.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs